A Phase 4 interventional study of Metformin 500mg in Parkinsons Disease (PD), sponsored by Jinnah Medical & Dental College. Not yet recruiting. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Jinnah Medical & Dental College · Phase 4, Interventional, and Supportive care
This study will evaluate whether metformin when it will be given to patients with Parkinson's disease along with standard therapy (levodopa carbidopa) will improve motor symptoms and decreases levels of alpha synuclein and MDA in patients with PD as compare to PD patients receiving only standard therapy (levodopa carbidopa)
Inclusion Criteria: :
Male and female patients diagnosed with primary PD age 50-70 years receiving levodopa + carbidopa. Diagnosis will be made in accordance with movement disorder society clinical diagnostic criteria for Parkinson's disease
Exclusion Criteria:
Secondary Parkinsonism co-morbid (such as Diabetes mellitus, Cardio-vascular diseases, Senile tremors, Wilson's disease, Cancers etc.) Pregnant and lactating mothers Sensitivity to metformin Lactic acidosis History of alcohol use
patients will continue standard therapy with carbidopa levodopa 250/25 mg TDS
patients will receive 500mg Metformin BD for 12 weeks along with standard treatment with carbidopa levodopa 250/25mg TDS
Drug: Metformin 500mg
Metformin will be given to the group B along with the standard treatment
MDS-UPDRS
Change in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score from baseline to 12 weeks to assess changes in Parkinson disease symptoms. The MDS-UPDRS (Movement Disorder Society-Unified Parkinson's Disease Rating Scale) is the standard scale used to assess the severity and progression of Parkinson's disease (PD) and response to treatment. It has 4 parts. Part I Non-motor experiences of daily living 52 Part II Motor experiences of daily living 52 Part III Motor examination performed by clinician 132 Part IV Motor complications of treatment, e.g., dyskinesia and fluctuations 24 Total score: 260 Each item is generally scored: 0 = Normal / no problem 1. = Slight 2. = Mild 3. = Moderate 4. = Severe Higher scores represents greater severity of Parkinson's disease.
Time frame: 12weeks
MDA levels
Change in malondialdehyde (MDA) levels from baseline to 12 weeks to asses changes in oxidative stress
Time frame: 12 weeks
Alpha Synuclein levels
Change in serum alpha-synuclein concentration from baseline to 12 weeks
Time frame: 12 weeks
Safety profile of metformin
Safety profile of the interventional drug (metformin) will be assed in Group B (intervention group) 30 patients. blood samples will be taken for blood (CBC) to check hemoglobin levels
Time frame: From baseline to Week 12
Safety Profile of Metformin
Safety profile of the interventional drug (metformin) will be assed in Group B (intervention group) 30 patients. blood samples will be taken to assess the Renal side effects of drug by measuring Urea, creatinine, GFR
Time frame: From baseline to week 12
Safety Profile of Metformin
Safety profile of the interventional drug (metformin) will be assed in Group B (intervention group) 30 patients. blood samples will be taken to assess the hepatic side effects of drug by measuring ALT,AST
Time frame: Baseline to weeks 12
Safety Profile of Metformin
Safety profile of the interventional drug (metformin) will be assed in Group B (intervention group) 30 patients. blood samples will be taken to assess the Cardiac side effects of drug by measuring TGs, HDL
Time frame: From baseline to week 12
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.